Literature DB >> 7270433

Value of exercise thallium-201 imaging in patients with diagnostic and nondiagnostic exercise electrocardiograms.

A S Iskandrian, B L Segal.   

Abstract

The role of exercise imaging with thallium-201 in the evaluation of patients suspected of having coronary artery disease was studied in 194 patients undergoing diagnostic coronary arteriography. Ninety-eight patients had 70 percent or more narrowing of one or more coronary vessels and 96 patients had either no or insignificant coronary artery disease. One hundren twenty-three of the 194 patients had conclusive treadmill exercise electrocardiograms (either positive or negative), and 71 had inconclusive exercise electrocardiograms. Fifty-four of the 98 patients with coronary artery disease were receiving propranolol at the time of testing. Forty-five (83 percent) of the 54 patients receiving propranolol and 33 (75 percent) of the 44 patients not receiving propranolol had abnormal exercise thallium images (difference not significant). In patients with conclusive exercise electrocardiograms the sensitivity of exercise imaging was not significantly different from that of exercise electrocardiograms (80 versus 74 percent), but the sensitivity of both tests combined (92 percent) was higher than that of either test alone (p less than 0.01). The specificity of exercise imaging (97 percent) electrocardiograms the sensitivity of exercise imaging was not significantly different from that of exercise electrocardiograms (80 versus 74 percent), but the sensitivity of both tests combined (92 percent) was higher than that of either test alone (p less than 0.01). The specificity of exercise imaging (97 percent) electrocardiograms the sensitivity of exercise imaging was not significantly different from that of exercise electrocardiograms (80 versus 74 percent), but the sensitivity of both tests combined (92 percent) was higher than that of either test alone (p less than 0.01). The specificity of exercise imaging (97 percent) was higher than that of exercise electrocardiograms (86 percent, p less than 0.02). The specificity of both tests combined was not significantly different from that of exercise electrocardiograms alone. The sensitivity (79 percent) and specificity (95 percent) of exercise imaging were not significantly different in patients with inconclusive exercise electrocardiograms when compared with those in patients whose exercise electrocardiograms were conclusive. These data indicate that exercise imaging is sensitive and specific in diagnosing coronary artery disease in the presence of diagnostic as well as nondiagnostic exercise electrocardiograms and that propranolol therapy does not affect the results.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7270433     DOI: 10.1016/0002-9149(81)90601-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Routine radionuclide techniques in evaluation of patients with suspected coronary heart disease.

Authors:  E Thaulow; K Rootwelt; J Erikssen; S Nitter-Hauge
Journal:  Br Heart J       Date:  1982-09

2.  Prognostic value of myocardial hypoperfusion indexes in patients with suspected or known coronary artery disease.

Authors:  M Petretta; A Cuocolo; A Carpinelli; E Nicolai; G Valva; V Bianchi; L Salemme; M Salvatore; D Bonaduce
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

3.  Exercise testing with myocardial perfusion imaging in patients with normal baseline electrocardiograms: cost savings with a stepwise diagnostic strategy.

Authors:  J A Mattera; S A Arain; A J Sinusas; L Finta; F J Wackers
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

4.  Additional value of thallium-201 SPECT to a conventional exercise test for the identification of severe coronary lesions after an episode of unstable coronary artery disease.

Authors:  J E Karlsson; A Björkholm; E Nylander; J Ohlsson; L Wallentin
Journal:  Int J Card Imaging       Date:  1995-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.